染料木黄酮与顺铂联用对耐药卵巢癌细胞SKOV-3的影响  

Effects of genistein combined with cisplatin on drug-resistant ovarian carcinoma cell SKOV-3

作　　者：袁鹏[1] 黄艳红[1] 辛晓燕[1] 宋晖[1] 田爽[1] 王德堂[1] 

机构地区：[1]第四军医大学西京医院妇产科,陕西西安710033

出　　处：《第四军医大学学报》2006年第3期199-201,共3页Journal of the Fourth Military Medical University

基　　金：国家自然科学基金(30472226)

摘　　要：目的：探讨染料木黄酮与顺铂联用对耐药卵巢癌细胞系SKOV-3增殖与凋亡的影响．方法：采用MTT比色法检测染料木黄酮和顺铂联用对SKOV-3细胞增殖的影响，Hoechst染色荧光显微镜下观察联合用药后细胞形态的改变，流式细胞仪分析细胞周期并检测凋亡率．结果：联用不同浓度的染料木黄酮后顺铂对SKOV-3细胞IC50降低率为32．3％-79．8％，两药联合作用系数在0．586-0．869之间，为轻度至高度协同作用．染料木黄酮与顺铂联用可显著提高凋亡率，两药联用诱导SKOV-3细胞凋亡和阻滞G2／M期、干扰S期进程，凋亡率与G1期细胞比例呈负相关（rs=-0．953，P〈0．05）．结论：染料木黄酮可以增强顺铂对SKOV-3细胞的增殖抑制作用和杀伤作用，两种药物具有协同作用．染料木黄酮阻滞细胞于G2／M期并同时干扰S期进程可能是两药发挥协同作用的重要机制．AIM： To investigate the effects of genistein combined with cisplatin on the proliferation and apoptosis of drugresistant ovarian carcinoma cell SKOV-3. METHODS： The growth inhibitory effect of genistein and cisplatin on SKOV-3 cells was studied by MTr growth assay, the morphological alterations of SKOV-3 cells were demonstrated by Hoechst 33342 staining under a fluorescence microscope and apoptosis and cell cycle distribution were detected by flow cytometry. RESULTS： Various concentrations of genistein in combination with cisplatin resulted in the reduction of ICs0 by 32.3% -79.8% in SKOV-3 cells. The combination index of genistein and cisplatin in SKOV-3 cells ranged from 0.586 to 0. 869, which indicated that they acted in a slightly to highly synergistic pattern. The apoptotic rate was also significandy raised by combination of genistein and cisplatin, which showed a relationship with G2/M arrest and the disturbance of S phase because there was a negative correlation between apoptotic rate and GI phase cell fraction（rs = -0.953, P 〈0.05）. CONCLUSION： Genistein can significantly improve the growth inhibition and cytotoxicity effects of cisplatin on SKOV-3 cells and the two agents act in a synergistic way. These synergistic effects may be related to the G2/M arrest and the disturbance of S phase by genistein.

关 键 词：染料木黄酮 顺铂 卵巢肿瘤 药物协同作用 

分 类 号：R730.53[医药卫生—肿瘤]